Group 1 - Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on CRISPR-based therapies aimed at revolutionizing medicine [2] - The company will present its first quarter 2025 financial results and operational highlights on May 8, 2025, at 8 a.m. ET [1] - A replay of the conference call will be available on Intellia's website starting May 8, 2025, at 12 p.m. ET [1] Group 2 - Intellia aims to develop novel, first-in-class medicines that address significant unmet medical needs and advance treatment paradigms [2] - The company is expanding its CRISPR-based platform with novel editing and delivery technologies to harness the full potential of gene editing [2]

Intellia Therapeutics, Inc. (NTLA) closed the last trading session at $8.48, gaining 19.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.79 indicates a 392.8% upside potential.The mean estimate comprises 24 short-term price targets with a standard deviation of $27.61. While the lowest estimate of $9 indicates a 6.1% increase from the current price level, the most optimistic a ...

SAN DIEGO, April 23, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of thoseNASDAQ: NTLA shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.On February 11, 2025, aNASDAQ: NTLA investor filed a lawsuit ag ...

Core Viewpoint - A class action lawsuit has been filed against Intellia Therapeutics for alleged violations of federal securities laws, specifically related to misleading statements about the development of its drug NTLA-3001 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Intellia provided false and misleading information regarding the viability of NTLA-3001, leading investors to believe that the company had reliable data on its development and marketing [2]. - It is alleged that the company's reports on timelines for future studies were not sustainable due to high costs and inefficiencies in delivery methods [2]. - The company reportedly struggled to provide timely doses of NTLA-3001 and maintain adequate staffing levels [2]. Group 2: Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [3]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [3].

Core Viewpoint - A class action lawsuit has been filed against Intellia Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements about the development of its drug NTLA-3001 [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that Intellia made false and misleading statements regarding its drug development and marketing strategies, particularly concerning NTLA-3001 [4]. - Investors who purchased Intellia's securities between July 30, 2024, and January 8, 2025, are encouraged to participate in the class action [2]. - The class has not yet been certified, meaning that potential class members are not currently represented by an attorney [3]. Group 2: Allegations Against the Company - The complaint alleges that Intellia provided investors with a false impression of having reliable information about NTLA-3001's development [4]. - It is claimed that the company's reports on timelines for future studies were unsustainable due to high costs and inefficient delivery methods [4]. - The company reportedly struggled to provide timely doses of NTLA-3001 and maintain adequate staffing levels, leading to materially misleading public statements [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Intellia Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's drug development programs [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $50,000 in Intellia between July 30, 2024, and January 8, 2025, to discuss their legal rights [1]. - There is an April 14, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Intellia [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Company Developments and Financial Impact - Intellia's complaint alleges that the company and its executives made false statements regarding the Phase 1/2 study of NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [4]. - On January 9, 2025, Intellia announced a strategic shift, focusing on drug candidates NTLA-2002 and nex-z, while discontinuing NTLA-3001, leading to a workforce reduction of approximately 27% [5]. - Following this announcement, Intellia's stock price fell by $1.82 per share, or 15.14%, closing at $10.20 per share on January 10, 2025 [6].

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit from investors who purchased securities during a specified period, alleging misleading statements regarding the viability of its drug development programs [1][4]. Company Overview - Intellia is a genome editing company focused on developing curative therapeutics, with a notable project being NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [3]. Allegations in the Lawsuit - The lawsuit claims that Intellia's management made false or misleading statements about the viability and development of NTLA-3001, including: - Misrepresentation of reliable information regarding NTLA-3001's development and marketing potential [4]. - Overly optimistic timelines for dosing and future studies that did not align with reality [4]. - Lack of capability to timely dose patients or maintain research and development for NTLA-3001 due to the challenges of viral-based editing methods [4]. - Concerns about the cost and inefficiency of viral-based editing drugs, even if NTLA-3001 was successful [4]. Impact of Company Reorganization - On January 9, 2025, Intellia announced a reorganization, prioritizing resources towards NTLA-2002 and nex-z, leading to the discontinuation of NTLA-3001. This announcement resulted in a stock price drop of over 15% [5].

NEW YORK, April 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=141927&from=4CLASS PERIOD ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Intellia Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Intellia securities is from July 30, 2024, to January 8, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Background - The lawsuit alleges that Intellia provided misleading information regarding its Phase 1/2 study for NTLA-3001, which is aimed at treating alpha-1 antitrypsin deficiency-associated lung disease [4]. - Defendants reportedly failed to disclose that demand for viral-based editing was declining as non-viral methods gained preference due to cost-effectiveness and efficiency [4]. - The lawsuit claims that when the true information became public, investors suffered damages [4].

NEW YORK, April 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Intellia and certain of i ...